Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22295781 | 0.82 | PTGS1 (0.40) | BRD4CYP1A2CYP2A6TSHRFFAR1 | |
| SCHEMBL30524232 | 0.82 | ALOX5 (0.47) | BRD4RAB9ANPC1CA12CA1 | |
| SCHEMBL12571878 | 0.82 | ALOX5 (0.47) | BRD4RAB9ANPC1CA12CA1 | |
| SCHEMBL20390159 | 0.81 | NPSR1 (0.48) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL1745297 | 0.80 | BRD4 (0.58) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL9914787 | 0.78 | BRD4 (0.51) | BRD4RAB9ANPC1CA12CA1 | |
| SCHEMBL9914780 | 0.78 | RAB9A (0.44) | BRD4RAB9ANPC1CA12CA1 | |
| SCHEMBL9914789 | 0.77 | NPC1 (0.43) | BRD4RAB9ANPC1CA12CA1 | |
| SCHEMBL30356316 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL28996482 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2A6TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | BRD4 2707/4885RAB9A 2933/4885NPC1 1425/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | BRD4 1593/4885RAB9A 2029/4885NPC1 1470/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | BRD4 277/4885RAB9A 3930/4885NPC1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.